Loading…
Medicinova Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -23.2% over 5Y.
today you would have $680.74▼ -31.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 20 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.31 | $2.10 | $1.50 | $2.05 | $2.68 | $5.26 | $6.74 | $8.17 | $6.47 | $6.03 | $3.55 | $3.04 | $2.14 | $1.64 | $1.70 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SPROSpero Therapeutics, Inc. | $1.20 | 8.6x | 1.6x | — | 19.17% | $69.88M |
| PLRXPliant Therapeutics Inc | $1.13 | — | 0.5x | — | -50.29% | $69.66M |
| XBITXBiotech Inc. | $2.27 | — | 0.5x | — | -29.94% | $69.21M |
| MDXHMDxHealth SA | $0.72 |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Company description provided by Yahoo Finance.
| $4.71 |
| $7.04 |
| $1.59 |
| $4.60 |
| $13.28 |
| P/S | 55.4x | 157.4x | — | 73.6x | — | 32.6x | — | — | — | — | — | — | — | — | 37.3x | — | — | — | — | — | — |
| P/B | 2.2x | 1.6x | 2.0x | 1.2x | 1.4x | 1.6x | 3.6x | 4.0x | 4.7x | 6.9x | 6.0x | 3.3x | 3.4x | 2.0x | 2.0x | 1.2x | 2.4x | — | — | — | — |
| EPS | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | -$0.31 | -$0.30 | -$0.36 | -$0.32 | -$0.33 | -$0.33 | -$0.38 | -$0.19 | -$0.66 | -$1.20 | -$1.63 | -$1.68 | — | — | — |
| Profit margin | -1111.46% | -2928.78% | — | -857.15% | — | -251.00% | — | — | — | — | — | — | — | — | -1365.76% | — | — | — | — | — | — |
| ROE | -28.87% | -28.85% | -21.05% | -13.74% | -20.03% | -12.11% | -19.42% | -17.28% | -20.07% | -28.89% | -31.47% | -27.01% | -41.78% | -15.84% | -73.66% | -75.47% | -81.72% | -50.91% | -45.63% | -73.42% | -35.34% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $68.77M |
| CSBRChampions Oncology Inc | $4.93 | — | 17.4x | — | -29.97% | $68.5M |
| PMVPPMV Pharmaceuticals, Inc. | $1.37 | — | 1.0x | — | -70.93% | $73.24M |